Recent research involving the Southwest Oncology Group (SWOG) Cancer Research Network indicate that patients with metastatic hormone receptor-positive breast cancer who experience low levels of the enzyme sTK1 in their blood serum during the commencement of anti-estrogen treatment may go on to live longer with their cancer in check based on the results of an important study.
Published recently in the journal Clinical Cancer Research, the study results reveal that those patients identified with low sTK1 activity levels are associated with slow-growing disease possibly manageable with single-drug endocrine therapy ongoing. Whether this particular patient cohort benefits from the addition of a CDK4/6 inhibitor as well is not certain as of yet.
The results reported recently by SWOG derive from an analysis of serum samples from 432 women with breast cancer who participated in a clinical trial termed SO226. Investigators found that most women with metastatic breast cancer live longer when they receive a combination of the endocrine therapy drugs anastrozole and fulvestrant compared to when they just receive anastrozole, reports Dr. Lajos Pusztai, MD, DPhil, profe...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).